MDX Meldex

    RNS Number : 7879D
  Meldex International PLC
  19 September 2008
   

 For Immediate Release  19 September 2008


    Meldex International Plc ("Meldex " or "the Company")

    Notification of Interim Results


    London, UK, 19 September 2008: Meldex (AIM: MDX), the specialty pharma and healthcare company announces it will report its Interim
Results for the six months ended 30 June 2008 on Tuesday 30 September, 2008.



    For further information:

    Buchanan Communications                     + 44 (0) 20 7466 5000
    Rebecca Skye Dietrich

    FinnCap, NOMAD                                      + 44 (0) 20 7600 1658
    Geoff Nash




    About Meldex International Plc
    Meldex International plc is an innovative specialty pharmaceutical and OTC product Company. Listed on London's AIM in May 2003, the
Company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic
alliances with several global healthcare companies. Meldex has acquired sales and marketing resources within Europe and the US as a launch
mechanism for its own pharmaceutical products. Meldex acquired the Melbrosin business in June 2007. Melbrosin's focus is on consumer over
the counter health care products based on substances of natural and plant origin which are developed into consumer orientated brands then
scaled, produced and distributed by Melbrosin. The Melbrosin complements the prescription pharmaceutical sales and marketing business
created and expanded in 2006.

    The business continues to develop innovative delivery mechanisms enhancing both its own product range and those of selected partners
using its proprietary XGELTM polymer technology. For further information please go to www.meldexinternational.com


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
NORKGGMLDRVGRZM

Meldex (LSE:MDX)
Historical Stock Chart
From Jun 2024 to Jul 2024

Meldex (LSE:MDX)
Historical Stock Chart
From Jul 2023 to Jul 2024